Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.
Journal
Pharmacogenetics and genomics
ISSN: 1744-6880
Titre abrégé: Pharmacogenet Genomics
Pays: United States
ID NLM: 101231005
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
pubmed:
28
9
2021
medline:
2
4
2022
entrez:
27
9
2021
Statut:
ppublish
Résumé
Integration of pharmacogenomics into clinical care is being studied in multiple disciplines. We hypothesized that understanding attitudes and perceptions of anesthesiologists, critical care and pain medicine providers would uncover unique considerations for future implementation within perioperative care. A survey (multiple choice and Likert-scale) was administered to providers within our Department of Anesthesia and Critical Care prior to initiation of a department-wide prospective pharmacogenomics implementation program. The survey addressed knowledge, perceptions, experiences, resources and barriers. Of 153 providers contacted, 149 (97%) completed the survey. Almost all providers (92%) said that genetic results influence drug therapy, and few (22%) were skeptical about the usefulness of pharmacogenomics. Despite this enthusiasm, 87% said their awareness about pharmacogenomic information is lacking. Feeling well-informed about pharmacogenomics was directly related to years in practice/experience: only 38% of trainees reported being well-informed, compared to 46% of those with 1-10 years of experience, and nearly two-thirds with 11+ years (P < 0.05). Regarding barriers, providers reported uncertainty about availability of testing, turnaround time and whether testing is worth financial costs. Anesthesiology, critical care and pain medicine providers are optimistic about the potential clinical utility of pharmacogenomics, but are uncertain about practical aspects of testing and desire clear guidelines on the use of results. These findings may inform future institutional efforts toward greater integration of genomic results to improve medication-related outcomes.
Identifiants
pubmed: 34570085
doi: 10.1097/FPC.0000000000000455
pii: 01213011-202204000-00001
pmc: PMC8940738
mid: NIHMS1728765
doi:
Banques de données
ClinicalTrials.gov
['NCT03729180']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-86Subventions
Organisme : NHGRI NIH HHS
ID : R01 HG009938
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007019
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000430
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Administration UFD. Table of pharmacogenomic biomarkers in drug labeling 2020. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling . [Accessed 22 May 2020]
Clinical Pharmacogenetics Implementation Consortium. What is CPIC? https://cpicpgx.org/ . [Accessed 22 May 2020]
PharmGKB. https://www.pharmgkb.org/ . [Accessed 22 May 2020]
Ubiqtuitous Pharmacogenomics. We want to make effective treatment optimization accessible to every European citizen. http://upgx.eu/ . [Accessed 22 May 2020]
Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526:343–350.
Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, et al. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin Pharmacol Ther 2018; 103:778–786.
Karas Kuzelicki N, Prodan Zitnik I, Gurwitz D, Llerena A, Cascorbi I, Siest S, et al. Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics 2019; 20:643–657.
Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci 2017; 106:2368–2379.
Borden BA, Galecki P, Wellmann R, Danahey K, Lee SM, Patrick-Miller L, et al. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics 2019; 29:31–38.
Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, et al. An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. Public Health Genomics 2014; 17:287–298.
Amara N, Blouin-Bougie J, Bouthillier D, Simard J. On the readiness of physicians for pharmacogenomics testing: an empirical assessment. Pharmacogenomics J 2018; 18:308–318.
Rafi I, Crinson I, Dawes M, Rafi D, Pirmohamed M, Walter FM. The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities. J Community Genet 2020; 11:269–277.
Varmus H. Getting ready for gene-based medicine. N Engl J Med 2002; 347:1526–1527.
Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012; 91:450–458.
Shields AE, Lerman C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin Pharmacol Ther 2008; 83:635–639.
Trinidad SB, Fryer-Edwards K, Crest A, Kyler P, Lloyd-Puryear MA, Burke W. Educational needs in genetic medicine: primary care perspectives. Community Genet 2008; 11:160–165.
Mountcastle-Shah E, Holtzman NA. Primary care physicians’ perceptions of barriers to genetic testing and their willingness to participate in research. Am J Med Genet 2000; 94:409–416.
Lesko LJ, Johnson JA. Academia at the crossroads: education and training in pharmacogenomics. Per Med 2012; 9:497–506.
Haga SB, Kim E, Myers RA, Ginsburg GS. Primary care physicians’ knowledge, attitudes, and experience with personal genetic testing. J Pers Med 2019; 9:E29.
Elewa H, Alkhiyami D, Alsahan D, Abdel-Aziz A. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J Eval Clin Pract 2015; 21:703–709.
Hoop JG, Lapid MI, Paulson RM, Roberts LW. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 “early adopting” departments of psychiatry. J Clin Psychiatry 2010; 71:745–753.
Dodson C. Knowledge and attitudes concerning pharmacogenomics among healthcare professionals. Per Med 2011; 8:421–428.
Tuteja S, Haynes K, Zayac C, Sprague JE, Bernhardt B, Pyeritz R. Community pharmacists’ attitudes towards clinical utility and ethical implications of pharmacogenetic testing. Per Med 2013; 10:793–800.
Kim WY, Kim HS, Oh M, Shin JG. Survey of physicians’ views on the clinical implementation of pharmacogenomics-based personalized therapy. Transl Clin Pharmacol 2020; 28:34–42.
Riddle D, Gregoski M, Baker K, Dumas B, Jenkins CH. Impressions of pharmacogenomic testing among certified registered nurse anesthetists: a mixed-method study. Pharmacogenomics 2016; 17:593–602.
Truong TM, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel RW, et al. The ImPreSS trial: implementation of point-of-care pharmacogenomic decision support in perioperative care. Clin Pharmacol Ther 2019; 106:1179–1183.
Cameron LD, Leventhal H. Self-regulation, health and illness: an overview. The Self-regulation of Health and Illness Behaviour. 2003.Routledge;
Marteau TM, Weinman J. Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med 2006; 62:1360–1368.
Rogers E. Diffusion of Innovations. 1995.Free Press;
Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, et al. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J 2019; 19:528–537.
O’Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, et al. Pharmacogenomics-based point-of-care clinical decision support significantly alters drug prescribing. Clin Pharmacol Ther 2017; 102:859–869.
O’Donnell PH, Danahey K, Jacobs M, Wadhwa NR, Yuen S, Bush A, et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project”. Am J Med Genet C Semin Med Genet 2014; 166C:68–75.
Friedman PN, Shaazuddin M, Gong L, Grossman RL, Harralson AF, Klein TE, et al. The ACCOuNT Consortium: a model for the discovery, translation, and implementation of precision medicine in African Americans. Clin Transl Sci 2019; 12:209–217.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–381.
Rahawi S, Naik H, Blake KV, Owusu Obeng A, Wasserman RM, Seki Y, et al. Knowledge and attitudes on pharmacogenetics among pediatricians. J Hum Genet 2020; 65:437–444.
DeLuca J, Selig D, Poon L, Livezey J, Oliver T, Barrett J, et al. Toward personalized medicine implementation: survey of military medicine providers in the area of pharmacogenomics. Mil Med 2020; 185:336–340.
van der Wouden CH, Bank PCD, Özokcu K, Swen JJ, Guchelaar HJ. Pharmacist-initiated pre-emptive pharmacogenetic panel testing with clinical decision support in primary care: record of PGx results and real-world impact. Genes (Basel) 2019; 10:E416.
Bain KT, Schwartz EJ, Knowlton OV, Knowlton CH, Turgeon J. Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). J Am Pharm Assoc (2003) 2018; 58:281–289 e281.
Bank PCD, Swen JJ, Schaap RD, Klootwijk DB, Baak-Pablo R, Guchelaar HJ. A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. Eur J Hum Genet 2019; 27:1532–1541.
Haga SB, LaPointe NM, Cho A, Reed SD, Mills R, Moaddeb J, et al. Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics 2014; 15:1677–1686.